Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer.
Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes. This review summarizes the pharmacology of ixapebilone and clinical trials with the drug both as a single agent and in combination. Data were obtained using searches of PubMed and abstracts of the annual meetings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium from 1995 to 2008. Ixapebilone is a semi-synthetic analog of epothilone B that acts to induce apoptosis of cancer cells via the stabilization of microtubules. Phase I clinical trials have employed various dosing schedules ranging from daily to weekly to 3-weekly. Dose-limiting toxicites included neuropathy and neutropenia. Responses were seen in a variety of tumor types. Phase II studies verified activity in taxane-refractory metastatic breast cancer. The FDA has approved ixabepilone for use as monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer. Ixabepilone is an efficacious option for patients with refractory metastatic breast cancer. The safety profile is similar to that of taxanes, with neuropathy and neutropenia being dose-limiting. Studies are ongoing with the use of both iv and oral formulations and in combination with other chemotherapeutic and biologic agents.
Puhalla
Shannon
S
UPMC Magee-Womens Cancer, Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Brufsky
Adam
A
Ann Oncol. 2007 Jul;18 Suppl 5:v9-15
17656562
J Clin Oncol. 2007 Aug 10;25(23):3407-14
17606974
Clin Cancer Res. 2005 Sep 1;11(17):6233-9
16144926
J Clin Oncol. 2006 May 1;24(13):2084-91
16648510
J Clin Oncol. 2001 Feb 15;19(4):1195-206
11181686
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Clin Cancer Res. 2004 Feb 15;10(4):1289-98
14977827
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9
10688884
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4256-61
10200249
Clin Cancer Res. 2002 Jul;8(7):2035-43
12114401
Invest New Drugs. 2006 Sep;24(5):441-6
16586011
J Clin Oncol. 2007 Nov 20;25(33):5210-7
17968020
J Clin Oncol. 2009 Feb 1;27(4):526-34
19075286
Cancer. 2007 Aug 1;110(3):556-63
17577218
Nature. 1995 Jun 1;375(6530):424-7
7760939
J Clin Oncol. 2005 Mar 1;23(7):1439-46
15735119
Ann Oncol. 2004 Jun;15(6):928-32
15151950
J Clin Oncol. 2008 Apr 10;26(11):1810-6
18347007
J Clin Oncol. 2005 Dec 1;23(34):8724-9
16314632
J Clin Oncol. 2007 Aug 10;25(23):3421-7
17606971
J Clin Oncol. 2005 Nov 1;23(31):7794-803
16172456
J Clin Oncol. 2005 May 1;23(13):3069-73
15860865
J Clin Oncol. 2007 Aug 10;25(23):3448-55
17606973
Cancer. 2013 May 1;119(9):1683-9
23310949
Drug Discov Today. 2001 Nov 15;6(22):1153-1164
11700217
J Clin Oncol. 2007 Aug 10;25(23):3415-20
17606972
N Engl J Med. 2008 Apr 17;358(16):1663-71
18420499
Biochemistry. 2002 Mar 26;41(12):3870-4
11900528
J Clin Oncol. 2003 May 1;21(9):1866-73
12721265
J Clin Oncol. 2005 Apr 20;23(12):2726-34
15837987
J Antibiot (Tokyo). 1996 Jun;49(6):560-3
8698639
Cancer Res. 2001 Apr 15;61(8):3369-72
11309294
Cancer Res. 1995 Jun 1;55(11):2325-33
7757983
Mol Cancer Ther. 2001 Nov;1(1):3-10
12467233
Ann Oncol. 2007 Jan;18(1):190-195
17018704
J Clin Oncol. 2007 Mar 20;25(9):1082-8
17261851
Invest New Drugs. 2007 Feb;25(1):63-7
16933153
Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8
17594093
Invest New Drugs. 2006 Nov;24(6):515-20
16699973
Cancer. 2005 May 1;103(9):1932-8
15800893
J Clin Oncol. 2008 Apr 1;26(10):1642-9
18375893
Clin Cancer Res. 2001 May;7(5):1429-37
11350914
Nat Rev Cancer. 2004 Apr;4(4):253-65
15057285
Invest New Drugs. 2007 Aug;25(4):335-41
17364235
J Clin Oncol. 2007 Aug 10;25(23):3399-406
17606975